Neupro Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neupro Clinical Development
You may also be interested in...
FDA Review of Schwarz’s Neupro Shaped By Parkinson’s Pharmacovigilance
FDA’s review of the Schwarz Neupro (rotigotine) NDA illustrates the important role pharmacovigilance has come to play in the agency’s consideration of new Parkinson’s disease treatments.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011